In the Claims:

Applicants hereby submit a clean version of each replacement claim. Please enter each claim.

1. (amended) A process for selecting phage that are resistant to blood inactivation, comprising:
   a. mixing a blood component with a phage display library; and,
   b. selecting for phage which are resistant to inactivation by the blood component.

2. (amended) A process for determining epitopes associated with specific parenchymal cells, comprising:
   a. preparing epitope display particles that are sized to exit a blood vessel and contact parenchymal cells;
   b. inserting the epitope display particles into a blood vessel; and,
   c. exposing the epitope display particles to the parenchymal cells where the epitope display particles associate with peptides specific to a cell;
   d. identifying cell specific epitopes.

3. (amended) The process of claim 1 wherein selection comprises multiple rounds of selection.

4. (amended) The process of claim 1 wherein the phage display library comprises T7 phage.

5. (amended) The process of claim 1 wherein the blood component is mixed with the phage display library *in vitro*.

6. (amended) The process of claim 1 wherein the blood component is mixed with the phage display library *in vivo*.

7. The process of claim 1 wherein a variable part of the phage DNA sequence is identified.

8. (amended) A phage that inhibits inactivation by blood components, comprising a phage having a coat peptide that protects the phage from antibody attack and inactivation.

9. (amended) The phage of claim 8 wherein the coat peptide carboxy terminus comprises a lysine or an arginine.

10. (amended) The phage of claim 8 wherein the peptide comprises a clone 20-6 peptide.

11. (amended) The process of claim 1 further comprising determining phage coat peptide interactions with antibodies using the selected phage.

12. The process of claim 11 wherein the selected phage is affinity purified.

13. (amended) The process of claim 11 wherein a phage coat protein's sequence is determined

14. (amended) A peptide for complexing with a drug to protect the drug from antibody inactivation during delivery, comprising determining a phage coat peptide sequence from the phage selected in claim 1 and associating the peptide with the drug to be delivered.

B4

15. (amended) The peptide of claim 14 wherein the peptide contains a carboxy terminal amino acid selected from the group consisting of arginine and lysine.

16. (amended) The peptide of claim 14 wherein the peptide contains a tyrosine.

Please amend claims 1-6, 8-11, and 13-16 as follows:

Version with markings to show changes made:

1. (Amended) [A process comprising: providing an epitope display system and exposing the epitope display system to blood products to identify useful epitopes.]

   A process for selecting phage that are resistant to blood inactivation, comprising:
   a. mixing a blood component with a phage display library; and,
   b. selecting for phage which are resistant to inactivation by the blood component.

2. (Amended) [A process for selecting phage that is resistant to blood inactivation, comprising:
   a. mixing a blood component with a phage display;
   b. selecting a phage; and,
   c. growing the selected phage in bacteria.]

   A process for determining epitopes associated with specific parenchymal cells, comprising:
   e. preparing epitope display particles that are sized to exit a blood vessel and contact parenchymal cells;
   f. inserting the epitope display particles into a blood vessel; and,
   g. exposing the epitope display particles to the parenchymal cells where the epitope display particles associate with peptides specific to a cell;
   h. identifying cell specific epitopes.

4. (Amended) [The process of claim 1 wherein the phage display comprises multiple rounds of selection.]

   The process of claim 1 wherein selection comprises multiple rounds of selection.

5. (Amended) [The process of claim 1 wherein the phage consists of a T7 phage.]

The process of claim 1 wherein the phage display library comprises T7 phage.

6. (Amended) [The process of claim 1 wherein the blood component is mixed with the phage display *in vitro*.]

The process of claim 1 wherein the blood component is mixed with the phage display library *in vitro.*

7. (Amended) [The process of claim 1 wherein the blood component is mixed with the phage display *in vivo*.]

The process of claim 1 wherein the blood component is mixed with the phage display library *in vivo.*

8. (Amended) [A peptide display library, comprising: a peptide that prevents phage inactivation.]

A phage that inhibits inactivation by blood components, comprising a phage having a coat peptide that protects the phage from antibody attack and inactivation.

9. (Amended) [The peptide display library of claim 8 wherein the peptide comprises lys+/arg+.]

The phage of claim 8 wherein the coat peptide carboxy terminus comprises a lysine or an arginine.

10. (Amended) [The peptide display library of claim 8 wherein the peptide comprises a clone 20-6 peptide.]

The phage of claim 8 wherein the peptide comprises a clone 20-6 peptide.

11. (Amended) [The process of claim 1 further comprising: selecting a phage resistant to inactivation and determining peptide-protein interactions using the selected phage.]

The process of claim 1 further comprising determining phage coat peptide interactions with antibodies using the selected phage.

13. (Amended) [The process of claim 11 wherein the protein's sequence is determined.]

The process of claim 11 wherein a phage coat protein's sequence is determined

14. (Amended) [A peptide specific for drug delivery, comprising: selecting a drug delivery peptide using the process of claim 1.]